Clinical Efficacy RisksRisks include failure to generate clear proof-of-concept clinical efficacy data showing the impact of ELI-002 7P in KRAS-mutated cancers.
Financial PerformanceElicio Therapeutics reported a net loss of $4.25 per share—wider than previously estimated net loss of $3.62 per share.
Trial UncertaintyThe bar-to-beat for the Phase 2 trial is unclear, as management hasn't disclosed powering assumptions, creating uncertainty about the trial's success metrics.